Selective serotonin reuptake inhibitors are still harmful and ineffective: Responses to the comments by Hieronymus et al.

Katakam Kiran Kumar*, Sethi Naqash Javaid, Janus Christian Jakobsen, Christian Gluud

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

89 Downloads (Pure)

Abstract

In this response, we address point by point the additional issues raised by Hieronymus et al. in their second round of critique of our systematic review on selective serotonin reuptake inhibitors for major depression. We repulse that we are biased or mistaken in any major ways. We acknowledge that we missed a few small, mostly unpublished trials, and we made a few minor errors in our systematic review. However, these omissions and errors neither have any impact on our overall results nor on our conclusions. The critique by Hieronymus et al. seems to raise questions about their understanding of the systematic review process, and, on several occasions, they wrongly claimed that we made errors. Our analyses should be impartial and free from any biases or prejudices as we do not have any obligation to support the interests of sponsors or other groups.

Original languageEnglish
JournalActa Neuropsychiatrica
Volume31
Issue number5
Pages (from-to)276-284
ISSN0924-2708
DOIs
Publication statusPublished - Oct 2019

Keywords

  • SSRI
  • antidepressants
  • clinical trials
  • depression
  • serotonin

Fingerprint

Dive into the research topics of 'Selective serotonin reuptake inhibitors are still harmful and ineffective: Responses to the comments by Hieronymus et al.'. Together they form a unique fingerprint.

Cite this